PainReform (PRFX)

Executive Summary

PainReform Ltd. (NASDAQ: PRFX) is a clinical-stage specialty pharmaceutical company focused on reformulating established local anesthetics for post-operative pain management. Its lead candidate, PRF-110, is an extended-release injectable formulation of ropivacaine designed to provide sustained pain relief after surgery, potentially reducing the need for opioids. The company recently completed a Phase 3 trial (NCT05773846) evaluating ropivacaine for bunionectomy pain, which could support regulatory filing. Additionally, PRF-110 has completed earlier-phase studies and is positioned for further development. PainReform’s strategy leverages known molecules to mitigate development risk while addressing a large market for non-opioid analgesics. With a market cap under $2 million, the stock is highly speculative but could see significant upside if PRF-110 advances or a partnership is secured. The company operates from Israel and has a small pipeline of reformulated candidates.

Upcoming Catalysts (preview)

• Q1 2027PRF-110 Phase 3 initiation or topline results40% success
• Q2 2026NDA submission for ropivacaine bunionectomy indication60% success
• TBDPartnership or licensing deal for PRF-11025% success